Followings are the Excellent Presentations selected by the Program Committee from those

presented at the 54th Annual Meeting of the Japan Society of Clinical Oncology (JSCO2016).

#### Number of presentations awarded the Excellent Presentations

34 (including 8 Best Presentations)

### Head and neck cancer

• Nivolumab vs investigator's choice for recurrent or metastatic (R/M) squamous cell

carcinoma of the head and neck (HNSCC)

Shunji Takahashi (Cancer Institute Hospital)

• Whole-exome sequencing and gene expression profiling in patients with head and neck

squamous cell carcinoma

Yoshiyuki Iida (Shizuoka Cancer Center Hospital)

• A Multicenter Study of Carbon Ion Radiotherapy for Head and Neck Adenocarcinoma:

Sub-analysis of the Japan Carbon Ion Radiotherapy Study Group (J-CROS) Study (1402

HN)

Jun-ichi Saitoh (Gunma University Heavy Ion Medical Center)

• Immunohistochemical Profiles and Prognostic Significance of Biomarker Expression in

Salivary Duct Carcinomas [Best Presentation]

Satoshi Kano (Hokkaido University)

#### **Oral cancer**

• A Study on T1-2N0M0 Tongue Squamous Cell Carcinoma [Best Presentation]

Mitsunobu Otsuru (Tokai University)

# Lung cancer

• Multi-institutional Retrospective Study of Carbon-ion Radiotherapy for Non-small cell

Lung Cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) [Best

#### Presentation]

Shioyama Y (SAGA-HIMAT Foundation)

• UGT1A1 polymorphism is associated with severe neutropenia following etoposide-based

chemotherapy in Japanese patients with small-cell lung cancer

Yutaka Negoro (University of Fukui Hospital)

**Breast cancer** 

• Predicting therapeutic effect by on tumor invasion lymphocytes (TILs) in endocrine

therapy for stage IV breast cancer

Yuka Asano (Osaka City University)

• The clinical impact of preoperative prognostic nutritional index in invasive breast

cancer.

Nami Yamashita (Kyushu University)

# Hepato-biliary-pancreatic cancers

• The outcomes of Project HOPE (High-tech Omics-based Patient Evaluation) and their

prognostic impact for hepatocellular carcinoma [Best Presentation]

Ryo Ashida (Shizuoka Cancer Center)

• Intensive systemic chemotherapy followed by S-1 and concurrent radiotherapy for

locally advanced pancreatic cancer. [Best Presentation]

Kentaro Sudo (Chiba Cancer Center)

• Key points in clinical trials for the poor- prognosis cases

Giichiro Tsurita (The IMSUT Hospital)

**Esophageal cancer** 

• Efficacy of combined endoscopic resection and chemoradiotherapy for clinical stage I

esophageal squamous cell carcinoma: a single-arm confirmatory study (JCOG0508).

Keiko Minashi (Japan Clinical Oncology Group)

#### **Gastric cancer**

• Phase III study of intraperitoneal paclitaxel plus S-1/paclitaxel compared with S-

1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial.

Ryoji Fukushima (Teikyo University)

• Predictive Biomarker analysis to Neoadjuvant Chemotherapy in Locally Advanced

Gastric Cancer

Kazuaki Tanabe (Hiroshima University)

# **Colorectal cancer**

• A randomized phase III trial of 1-year adjuvant chemotherapy with oral tegafur-uracil

(UFT) vs. surgery alone in stage II colon cancer: SACURA trial

Shoichi Fujii (Yokohama City University Medical Center)

• Influence of comorbidity and age on prognosis and application of adjuvant

chemotherapy in colorectal cancer patients pooled in Study Group of Surveillance after

Colorectal Cancer Surgery

Tomoki Yamano (Hyogo College of Medicine)

 International phase III randomized, non-inferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: compliance and safety of phase III Japanese ACHIEVE trial [Best Presentation]

J. Hasegawa (Osaka Rosai Hospital)

• Postoperative outcomes of cytoreductive surgery for treatment of pseudomyxoma

peritonei based on intraoperative peritoneal cancer index.

Akiyoshi Mizumoto (Kusatsu General Hospital)

# Gynecologic cancers

• Application of Trans-Applicator Intracavitary Radial Ultrasonography Imaging in the

Brachytherapy Treatment for Cervical Cancer

Tomoaki Tamaki (Fukushima Medical University; Saitama Medical University; Gunma

University)

# Renal and urothelial cancers

• Prognostic Significance of Early Tumor Shrinkage under Second-line Targeted Therapy

for Metastatic Renal Cell Carcinoma: A Retrospective Multiinstitutional Study in Japan

Hideaki Miyake (Hamamatsu University School of Medicine)

• Clinical features of patients with metastatic renal cancer in whom tumors were first

diagnosed as papillary renal cell carcinoma and finally as other renal cancers after a

central review: A multi-institutional study in the Japanese Society of Renal Cancer

Keiichi Ito (National Defense Medical College)

• Immunological Classification in Renal Cell Carcinoma Based on Immunocheckpoint

Molecules: The relationship with tumor aggressiveness and the presence of intra-tumor

diversity

Atsunari Kawashima (Osaka University)

• The assessment of renal cell carcinoma by FDG PET/CT predict the response to

molecular- targeted therapy

Noboru Nakaigawa (Yokohama City University)

• The impact of tumor size on survival of pT3aN0/xM0 RCC patients

Tomomi Kamba (Kyoto University)

• Effectiveness of platinum-based adjuvant chemotherapy for muscle-invasive bladder

cancer, a weighted propensity score analysis

Fumitaka Shimizu (Juntendo Nerima Hospital)

# Sarcomas of the soft tissues and bone

• Final results of a randomized phase II study comparing trabectedin and best supportive

care in patients with translocation-related sarcomas.

Tomoki Nakamura (Mie University Hospital)

# Cancer stem cells

• Application of Molecule V expressing on the cell surface of both cancer and cancer stem

like cells to cancer immune therapy [Best Presentation]

Masanori Fuse (National Cancer Center)

#### Management of adverse reaction

• Comprehensive study of risk factors for chemotherapy-induced nausea and vomiting in

cancer patients receiving cisplatin-based chemotherapy: a TRIPLE Pharmacogenomics

Study

Mari Yokoi (University of Shizuoka)